(vi) Differential Approaches.

(vii) Decentralised Planning.

(viii) Intersectoral coordination.

(ix) Strengthening administrative infrastructure.

(x) New approaches in IEC.

(xi) Monitoring & Evaluation mechanisms.

(xii) Research.

(xiii) Mechanisms for securing commitment and support of leadership.

(xiv) Role of organised sector.

(xv) Other family welfare related issues in population control.

(xvi) Financing of family welfare programmes.

(xvii) Incentives and disincentives.

(xviii) Disqualifying for elective posts if a person violates the small family norm.

(xix) Formulation of a National Population Policy.

Use of drug for migrain pain

699. SHRI S. MADHAVAN: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to refer to answer to Unstarred Question 2838 given in the Rajya Sabha on 18th August, 1993 and state:

(a) whether it is a fact that Migril, a common medicine prescribed for migrain pain impairs kidney function and causes high blood pressure: and

(b) if so, what steps are being taken to ban such harmful medicines?

THE MINISTER OF HEALTH AND FAMILY WELFARE SHRI B. SHANKARANAND): (a) The drug "Migril" is contra-indicated and not to be prescribed in cases of patients having high blood pressure or impaired liver or kidney functions.

(b) "Migril" is no longer manufactured in the country.

Clearance for marketing of depoprovera contraceptive

700. SHRI G. G. SWELL: Will the Minister of HEALTH AND FAMILY WELFARE be please to state:

(a) whether the Drug Controller has given unconditional clearance for marketting the injectible contraceptive Depoprovera;

(b) whether trial with Norplant implant has been successful and guarantee can be given that it will have no adverse effect on a woman; and

(c) whether protests from women organisations have fizzled out?

THE MINISTER OF HEALTH AND FAMILY WELFARE SHRI B. SHANKARANAND): (a) On the recommendation of experts the Drug Controller of India has given permission for marketing DEPO PROVERA subject to the following conditions:

(i) The product shall be marketed against prescription of a Registered Medical Practitioner.

(ii) The Marketing Company should carry out a post marketing surveillance study in consultation with the ICMR.

(b) Norplant I is still under phase three clinical trials by ICMR.

(c) A few representations have been received from some women organisations.

Standard of Indian Medical Science

701. SHR G. G. SWELL: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Indian medical science has reached world standard and has demonstrated capacity to set a chain of corporate health care units that will take care of the needs of the country and also foreigners that will earn the country substantial foreign exchange; and